A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies

Leukemia

Volumn 13, Issue 4, 1999, Pages 614-617

  Niehues, T ^a   Kapaun, P ^b   Harms, D O ^b   Burdach, S ^b   Kramm, C ^b   Korholz D ^b   Janka Schaub, G ^b   Gobel U ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

Immunophenotype; T cell selection; T All

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLASSIFICATION; CLINICAL PROTOCOL; GERMANY; HUMAN; IMMUNOPHENOTYPING; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; THYMOCYTE;

EID: 0032915797     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401382     Document Type: Article

References (20)

1. Haynes BF. Ontogeny of T cell precursors: a model for the initial stages of human T cell development. Immunol Today 1989; 10: 87-91.
2. Porcelli SA. The CD1 family: a third lineage of antigen presenting molecules. Adv Immunol 1995; 59: 1-98.
3. Kisielow P, von Boehmer H. Development and selection of T cells: facts and puzzles. Adv Immunol 1995; 58: 87-209.
4. Janka-Schaub CF, Harms D, Goebel U, Graubner U, Gutjahr P, Haas RJ, Juergens H, Spaar HJ, Winkler K. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - follow up after 9 years. COALL Study Group. Eur J Pediatr 1996; 155: 640-648.
5. Janka GE, Göbel U, Graubner U, Haas RJ, Jürgens H, Spaar H, Winkler K for the COALL study group. Improved prognosis for childhood acute lymphoblastic leukemia with very high blood count (>100/nl) with rotation of non cross-resistant drug combinations. Hematol Blood Transf 1990; 33: 489-492.
6. Harms D, Spaar HJ, Jorch N, Graubner U, Siegert E, Göbel U, Janka-Schaub GE for the COALL study group. Randomized comparison of 6-mercaptopurine (6-MP) vs. 6-thioguanine (6-TG) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL): differing hematological toxicity (manuscript in preparation).
7. European Group for the Immunological Characterization of Leukemias (EGIL): Bene MC, Castoldi, G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783-1786.
8. Roper M, Crist WM, Metzger R, Ragab AH, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD. Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 1983; 61: 830-837.
9. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE. Clinical features and outcome in childhood T-cell leukemia - lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group study. Blood 1988; 72: 1891-1897.
10. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA 1980; 77: 1588-1592.
11. Ludwig WD, Harbott J, Bartram CR, Komischke B, Sperling C, Teichmann JV, Seibt-Jung H, Notter M, Odenwald E, Nehmer A, Thiel E, Riehm H. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia patients. Experience of the BFM Study 86. In: WD Ludwig, Thiel E (eds). Recent Results in Cancer Research, Vol 131. Springer verlag: Berlin, Heidelberg, 1993, pp 269-288.
12. Uckun FM, Steinherz PG, Sather II, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1996; 88: 4288-4295.
13. Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman-GH. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997; 15: 2214-2221.
14. Andjelic S, Drappa J, Lacy E, Elkon KB, Nikolic-Zugic K. The onset of Fas-expression parallels the acquisition of CD4 and CD8 in fetal and adult ab thymocytes. Int Immunol 1994; 6: 73-80.
15. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
16. Killeen N, Stuart SG, Littman DR. Development and function of T cells in mice with a disrupted CD2 gene. EMBO J 1992; 11: 4329-4336.
17. Thiel F, Kranz BR, Raghavachar A, Bartram CR, Löffler H, Messerer D, Ganser A, Ludwig WD, Büchner T, Hoelzer D. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73: 1247-1258.
18. Garand R, Voisin S, Papin S, Praloran V, Lenormand B, Favre M, Philip P, Bernier M, Vanhaecke D, Falkenrodt A, Bene MC, Faure G and the Groupe d'Etude Immunologique des Leucemies. Characteristics of pro-T-ALL subgroups: comparison with late T-ALL. Leukemia 1993; 7: 161-167.
19. Ferrara F, Cimino R, Antinolfi I, de Rosa C, Mele G, Mettivier V, Fusco C, del Vecchio L. Clinical relevance of immunological dissection in T-ALL: a report on 20 cases with stem cell (CD7+, CD4-, CD8-, CD1) phenotype. Ami Hematol 1992; 40: 98-102.
20. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky GK, Sandlund JT, Crist WM, Raimondi SC. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174-179.